Clémence Henon

Clémence Henon

Auto-generated profile, based on publicly available information

Clémence Henon

Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Annals of Oncology
Verified
Journal Article
Closed access
CHC. Henon
C. Henon
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
CMC. Massard
C. Massard
OMO. Mir
O. Mir
RBR. Bahleda
R. Bahleda
ACAxel Le Cesne
Axel Le Cesne

18 August 2023 in Science Advances
Verified
Journal Article
Open access
Francesco BaschieriFrancesco Baschieri
Francesco Baschieri
AIAbigail Illand
Abigail Illand
JBJorge Barbazán
Jorge Barbazán
OZOlivier Zajac
Olivier Zajac
CHClémence Henon
Clémence Henon
GMGuillaume Montagnac
Guillaume Montagnac
Fibroblasts play a fundamental role in tumor development. Among other functions, they regulate cancer cells’ migration through rearranging the extracellular matrix, secreting soluble factors, and establishing direct physical contacts with cancer cells. Here, we report that migrating fibroblasts deposit on the substrate a network of tubular structures that serves as a guidance cue for cancer cell migration. Such membranous tubular network, hereafter called tracks, is stably anchored to the substrate in a β5-integrin–dependent manner. We found that cancer cells specifically adhere to tracks by using clathrin-coated structures that pinch and engulf tracks. Tracks thus represent a spatial memory of fibroblast migration paths that is read and erased by cancer cells directionally migrating along them. We propose that fibroblast tracks represent a topography-based intercellular communication system capable of steering cancer cell migration.

1 January 2017 in ESMO Open
Verified
Journal Article
Open access
PDF file
CHClémence Henon
Clémence Henon
DLDelphine Lissa
Delphine Lissa
XPXavier Paoletti
Xavier Paoletti
CTConstance Thibault
Constance Thibault
Christophe Le TourneauChristophe Le Tourneau
Christophe Le Tourneau
SPSophie Postel-Vinay
Sophie Postel-Vinay
Background Phase I experts recommend revisiting dose-limiting toxicity (DLT) definition to include chronic and cumulative toxicities induced by new molecularly targeted therapies. Patient’s assessment of late toxicities’ tolerability is, however, unknown. Materials and methods A prospective survey on adverse events (AEs) tolerability on 23 National Cancer InstituteCommon Terminology Criteria for Adverse Event, Version 4 (NCI-CTCAE.v4) items was conducted at Gustave Roussy’s Phase I department. Patients’ maximum tolerability duration was recorded at baseline, during trial and at trial completion. Results were compared with the corresponding physicians’ survey. Results 52 patients enrolled in 27 Phase I trials between May 2014 and November 2015 completed 102 forms. At baseline, the most feared G2/G3 AEs were haematuria (74%), vomiting (71%) and hyperglycemia (64%)/dry mouth (94%), hyperglycemia (92%) and vomiting (92%). At trial completion, the most feared G2/G3 AEs were personality change (83.3%), haematuria (82%) and fever (80%)/dry mouth, fever and dizziness (100% each). Tolerability score did not differ over time. More previous treatments and occurrence of severe AEs were associated with better tolerability at study completion (p=0.0234 and p=0.0153, respectively, in multivariate analysis). Patient’s tolerability differed from physician’s assessment. Conclusion AEs considered intolerable by patients are toxicities that directly impact their quality of life and differ from those feared by physicians or included in DLT definition. Patient-reported tolerability of AEs may help in optimising drug development.

16 October 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS–WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in treating DSRCT have not occurred for over two decades. To identify effective therapeutic approaches to target DSRCT, we conducted a high-throughput drug sensitivity screen in a DSRCT cell line assessing chemosensitivity profiles for 79 small-molecule inhibitors. DSRCT cells were sensitive to PARP inhibitors (PARPi) and ataxia–telangiectasia and Rad3–related inhibitors (ATRi), as monotherapies and in combination. These effects were recapitulated using multiple clinical PARPi and ATRi in three biologically distinct, clinically relevant models of DSRCT, including cell lines, a patient-derived xenograft–derived organoid model, and a cell line–derived xenograft mouse model. Mechanistically, exposure to a combination of PARPi and ATRi caused increased DNA damage, G2–M checkpoint activation, micronuclei accumulation, replication stress, and R-loop formation. EWS–WT1 silencing abrogated these phenotypes and was epistatic with exogenous expression of the R-loop resolution enzyme RNase H1 in reversing sensitivity to PARPi and ATRi monotherapies. The combination of PARPi and ATRi also induced EWS–WT1–dependent cell-autonomous activation of the cyclic GMP–AMP synthase–stimulator of IFN genes innate immune pathway and cell-surface expression of PD-L1. Taken together, these findings point toward a role for EWS–WT1 in generating R-loop–dependent replication stress that leads to a targetable vulnerability, providing a rationale for the clinical assessment of PARPi and ATRi in DSRCT. Significance: EWS–WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors, supporting the potential of these drugs in treating patients with this aggressive sarcoma subtype.

31 July 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
MTMaud Toulmonde
Maud Toulmonde
TVThibaud Valentin
Thibaud Valentin
NFNelly Firmin
Nelly Firmin
SWSarah Watson
Sarah Watson
ACAxel Le Cesne
Axel Le Cesne
Liposarcomas (LPS) are among the most common sarcomas, but gather a diversity of rare to ultrarare molecular subtypes whose presentations and natural histories are partially characterized. The aim of the work was to describe the presentation and outcome of the different LPS histotypes from the NETSARC+ registry. NETSARC+ (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB), funded by the French INCA since 2010 aiming to improve the quality of care of sarcoma patients. Patients’ characteristics, treatment and outcomes are collected in a nationwide database. This work describes the outcome of all LPS confirmed by central review pathology review and integrated between 2010 and 2023 in the NETSARC+ database. 11,132 liposarcomas are included in the database for an estimated incidence of 11.5/106/y. Median age was 65 (Q1–Q3: 53–74, range 0–97 y), with 6529 males (58.7%), with 4220 (37.9%) dedifferentiated (DDLPS), 1838 (16.5%) well differentiated LPS (WDLPS) & 2424 (21.8%) atypical lipomatous tumours (ALT), 1371 (12.3%) myxoid LPS (MyxLPS), 450 (4.0%) pleomorphic LPS (PLPS), 177 (1.6%) high grade myxoid LPS (HGMLPS), 24 (0.2%) mixed type liposarcomas (MTLPS), 14 (0.1%) myxoid pleomorphic LPS (MPLPS) and 614 (5.5%) non classified LPS (NCLPS). Age, sex and sites differed across histotypes, but overall, all histotypes were represent in all age groups and sites. We report first on a difference in the sex ratio of liposarcoma in different age groups. Women were less frequently affected with liposarcomas after 50, in DDLPS, MyxLPS and HGMLPS. The median overall survival of DDLPS was 144 months, significantly worse than that of MyxLPS (HR: 0.26 [95% CI 0.21–0.33]), PLPS (HR: 0.76 [95% CI 0.59–0.98]), HGMLPS (HR: 0.30 [95% CI 0.18–0.50]), WDLPS (HR: 0.30 [95% CI 0.24–0.37]), unclassified LPS (HR: 0.53 [95% CI 0.37–0.75]). In addition to a lower incidence, women aged >50 had a better relapse free and overall survival than male, while this was not observed in the group aged 50 or under. In multivariate analyses, size and age were independent prognostic factors for the most common subgroups, but specific prognostic parameters were observed in each molecular subgroup. Female >50 was an independent favorable prognostic factor for the largest groups of DDLPS. In this nationwide series of pathology-confirmed LPS, the clinical presentation, management and survival of histotypes are very different with age-related sex differences favoring women >50. DDLPS is the subtype with the worse prognosis. This work was supported by the following grants: NetSARC+ (INCA), RREPS (INCA), RESOS (INCA), INTERSARC+ (INCA), 10.13039/501100022238 LabEx DEvweCAN (ANR-10-LABX-0061), LYriCAN+ (INCa-DGOS-INSERM-ITMO cancer_18,003), Ligue Nationale contre le Cancer, 10.13039/501100004099 Ligue Contre le Cancer (Comité de l’Ain), 10.13039/501100004097 Fondation ARC , and EURACAN (EU project 739521).

21 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMartha J. Carreño-Gonzalez
Martha J. Carreño-Gonzalez
KHKimberley M. Hanssen
Kimberley M. Hanssen
ASAhmed Sadik
Ahmed Sadik
AHAlessa L. Henneberg
Alessa L. Henneberg
MKMaximilian M. L. Knott
Maximilian M. L. Knott
TGThomas G. P. Grünewald
Thomas G. P. Grünewald
How activational changes of driver oncogenes can promote metabolic reprogramming and cancer progression is largely uncharted territory. To address this issue, we employed Ewing sarcoma (EwS) as a model as it is driven by a single driver oncogene, namely chimeric EWSR1::ETS fusion transcription factors, whose fluctuating expression levels promote diverse transcriptional programs. While EWSR1::ETS-high cells display a rather sessile but proliferative phenotype and EWSR1::ETS-low cells are more invasive, the mechanisms underlying these different phenotypes remain poorly characterized. Here, using an integrative functional genomics approach, we show that low EWSR1::ETS fusion activity in patient tumors associates with poor outcome and increased signaling of the aryl hydrocarbon receptor (AHR). AHR signaling enrichment correlates with increased tumor infiltration by immunosuppressive cells and worse overall patient survival. Knockdown of EWSR1::ETS in EwS spheroid models cultured in human plasma-like media strongly alters tryptophan metabolism resulting in increased secretion of the AHR ligand kynurenine. Silencing of EWSR1::ETS reduced killing of EwS cells by natural killer (NK) cells, while AHR silencing increases NK cell-mediated killing. From a cell-intrinsic perspective, AHR knockdown inhibits proliferation, clonogenic, and spheroidal growth of EwS cells in vitro, which can be recapitulated by pharmacological AHR inhibition. Furthermore, AHR knockdown decreases tumor growth and metastasis in vivo. Collectively, our results illustrate how oncogene-mediated metabolic reprogramming of amino acid metabolism can translate into more aggressive disease phenotypes in cancer.